TRIPLE THERAPY FOR AGE-RELATED MACULAR DEGENERATION
- 1 June 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Retina
- Vol. 29 (6), S8-S11
- https://doi.org/10.1097/iae.0b013e3181ad253d
Abstract
Choroidal neovascularization is a hallmark sign of wet age-related macular degeneration (AMD) but it is not an isolated feature. Several processes are likely to contribute to the fibrotic scarring and vision loss that accompanies progressive disease. In a case series, a triple therapy approach to wet AMD was based on the goals of halting choroidal neovascularization, controlling the inflammatory response, and modifying proliferative factors. To address each of these goals, respectively, patients received photodynamic therapy, bevacizumab, and the steroid dexamethasone. The encouraging rate of response, including significant improvements in visual acuity, is consistent with the combined activities of these agents and provides the basis for more definitive studies.Keywords
This publication has 4 references indexed in Scilit:
- Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal NeovascularizationAmerican Journal of Ophthalmology, 2008
- TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- Triple Therapy of Intravitreal Triamcinolone, Photodynamic Therapy, and Pegaptanib Sodium for Choroidal NeovascularizationAmerican Journal of Ophthalmology, 2006
- Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium–Derived FactorPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2003